President and CSO
Dr. Vicki Nienaber has been a leader in the fragment-based drug discovery field since its inception at Abbott laboratories during the 1990's. At Abbott, she worked alongside NMR screeners pairing SARbyNMR with x-ray for drug discovery and is primary inventor of the first crystallographic screening method still in use today.
Dr. Nienaber has led numerous programs including SGX collaborations with Eli Lilly, Novartis and SGX internal FBLD pipeline. Dr. Nienaber also built the fragment screening platform at Abbott laboratories including invention of the first crystal mounting robot (ACTOR, now marketed by Rigaku). She also fully implimented the structural biology platform at SGX coordinating between engineers, programmers and scientists.
Marketing and Communications
Ms. Zehm has been a member of the Zenobia team since 2009. Before coming to Zenobia, She worked at the non-profit, Freedom is not Free, supporting families of veterans impacted by the wars in the middle east.
At Zenobia, Ms. Zehm has been responsible for all of the marketing and communcations surrounding the Zenobia Fragments product line.